MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer
Background: Sporadic colorectal cancers often arise from a region of cells characterized by a “field defect” that has not been well defined molecularly. DNA methylation has been proposed as a candidate mediator of this field defect. The DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) i...
Gespeichert in:
| Veröffentlicht in: | JNCI : Journal of the National Cancer Institute 2005-09, Vol.97 (18), p.1330-1338 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 1338 |
|---|---|
| container_issue | 18 |
| container_start_page | 1330 |
| container_title | JNCI : Journal of the National Cancer Institute |
| container_volume | 97 |
| creator | Shen, Lanlan Kondo, Yutaka Rosner, Gary L. Xiao, Lianchun Hernandez, Natalie Supunpong Vilaythong, Jill Houlihan, P. Scott Krouse, Robert S. Prasad, Anil R. Einspahr, Janine G. Buckmeier, Julie Alberts, David S. Hamilton, Stanley R. Issa, Jean-Pierre J. |
| description | Background: Sporadic colorectal cancers often arise from a region of cells characterized by a “field defect” that has not been well defined molecularly. DNA methylation has been proposed as a candidate mediator of this field defect. The DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) is frequently methylated in colorectal cancer. We hypothesized that MGMT methylation could be one of the mediators of field cancerization in the colon mucosa. Methods: We studied MGMT promoter methylation by three different bisulfite-based techniques in tumor, adjacent mucosa, and nonadjacent mucosa from 95 colorectal cancer patients and in colon mucosa from 33 subjects with no evidence of cancer. Statistical tests were two-sided. Results: MGMT promoter methylation was present in 46% of the tumors. Patients whose cancer had MGMT promoter methylation also had substantial MGMT promoter methylation in apparently normal adjacent mucosa. This methylation was seen with a quantitative assay in 50% (22/44; 95% confidence interval [CI] = 34% to 65%) of normal samples with MGMT promoter methylation in the adjacent tumors, 6% (3/51; 95% CI = 1% to 16%) of samples without MGMT methylation in adjacent tumors, and 12% (4/33; 95% CI = 3% to 28%) of control samples (P |
| doi_str_mv | 10.1093/jnci/dji275 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_68606470</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>20439127</sourcerecordid><originalsourceid>FETCH-LOGICAL-c516t-e20f938faf885d3a715d6bc9a3933a138c27a15ed0e21c15e19e84ce9ebe47bf3</originalsourceid><addsrcrecordid>eNqF0c1rFDEYBvBQlHZbPXkvQdCLjM33x1G2tmvpotBqxUvIZt6hWWcn22QW2v_eLLtY8GIuCcmPB_I-CL2h5CMllp8thxDP2mVkWh6gCRWKNIwS-QJNCGG6MUaLI3RcypLUZZk4REdUUS2MFBM0m1_Ob_G3nFZphIznMN4_9X6MacB-aPFFhL7F59BBGHEc8M06Zd_GgKepT7le-h5P_RAgv0IvO98XeL3fT9D3i8-301lz_fXyy_TTdRMkVWMDjHSWm853xsiWe01lqxbBem4595SbwLSnEloCjIZ6oBaMCGBhAUIvOn6C3u9y1zk9bKCMbhVLgL73A6RNccooooQm_4WMCG4p0xW-_Qcu0yYP9ROOMWKNIVRU9GGHQk6lZOjcOseVz0-OEretwW1rcLsaqj7dR24WK2if7X7uFbzbA1-C77tcZxjLs9NUS823Qc3OxTLC4993n387pbmWbvbzl_txd3dDr66IU_wPbameww</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>220988014</pqid></control><display><type>article</type><title>MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer</title><source>Oxford University Press Journals All Titles (1996-Current)</source><source>MEDLINE</source><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><creator>Shen, Lanlan ; Kondo, Yutaka ; Rosner, Gary L. ; Xiao, Lianchun ; Hernandez, Natalie Supunpong ; Vilaythong, Jill ; Houlihan, P. Scott ; Krouse, Robert S. ; Prasad, Anil R. ; Einspahr, Janine G. ; Buckmeier, Julie ; Alberts, David S. ; Hamilton, Stanley R. ; Issa, Jean-Pierre J.</creator><creatorcontrib>Shen, Lanlan ; Kondo, Yutaka ; Rosner, Gary L. ; Xiao, Lianchun ; Hernandez, Natalie Supunpong ; Vilaythong, Jill ; Houlihan, P. Scott ; Krouse, Robert S. ; Prasad, Anil R. ; Einspahr, Janine G. ; Buckmeier, Julie ; Alberts, David S. ; Hamilton, Stanley R. ; Issa, Jean-Pierre J.</creatorcontrib><description>Background: Sporadic colorectal cancers often arise from a region of cells characterized by a “field defect” that has not been well defined molecularly. DNA methylation has been proposed as a candidate mediator of this field defect. The DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) is frequently methylated in colorectal cancer. We hypothesized that MGMT methylation could be one of the mediators of field cancerization in the colon mucosa. Methods: We studied MGMT promoter methylation by three different bisulfite-based techniques in tumor, adjacent mucosa, and nonadjacent mucosa from 95 colorectal cancer patients and in colon mucosa from 33 subjects with no evidence of cancer. Statistical tests were two-sided. Results: MGMT promoter methylation was present in 46% of the tumors. Patients whose cancer had MGMT promoter methylation also had substantial MGMT promoter methylation in apparently normal adjacent mucosa. This methylation was seen with a quantitative assay in 50% (22/44; 95% confidence interval [CI] = 34% to 65%) of normal samples with MGMT promoter methylation in the adjacent tumors, 6% (3/51; 95% CI = 1% to 16%) of samples without MGMT methylation in adjacent tumors, and 12% (4/33; 95% CI = 3% to 28%) of control samples (P<.001 for comparison between each of the latter two groups and the first group). MGMT methylation was detected with a more sensitive assay in 94%, 34%, and 27% of these samples, respectively (P<.001). In grossly normal colonic mucosa of colon cancer patients, methylation was detected 10 cm away from the tumor in 10 of 13 cases. Tumors with MGMT promoter methylation had a higher rate of G-to-A mutation in the KRAS oncogene than tumors without MGMT promoter methylation (10/42 versus 3/46, P = .03). Using a sensitive mutant allele-specific amplification assay for KRAS mutations, we also found KRAS mutations in 12% (3/25; 95% CI = 2.5% to 31%) of colorectal mucosas with detectable MGMT methylation and 3% (2/64; 95% CI = 0.4% to 11%) of colorectal mucosas without MGMT methylation (P = .13). Conclusion: Some colorectal cancers arise from a field defect defined by epigenetic inactivation of MGMT. Detection of this abnormality may ultimately be useful in risk assessment for colorectal cancer.</description><identifier>ISSN: 0027-8874</identifier><identifier>EISSN: 1460-2105</identifier><identifier>DOI: 10.1093/jnci/dji275</identifier><identifier>PMID: 16174854</identifier><identifier>CODEN: JNCIEQ</identifier><language>eng</language><publisher>Cary, NC: Oxford University Press</publisher><subject>Biological and medical sciences ; Biomarkers, Tumor - genetics ; Cell Line, Tumor ; Clinical trials ; Colorectal cancer ; Colorectal Neoplasms - enzymology ; Colorectal Neoplasms - genetics ; Colorectal Neoplasms - pathology ; Deoxyribonucleic acid ; DNA ; DNA Methylation ; Epigenesis, Genetic ; Gastroenterology. Liver. Pancreas. Abdomen ; Gene Silencing ; Humans ; Intestinal Mucosa - enzymology ; Intestinal Mucosa - pathology ; Medical sciences ; Mutation ; O-Methylguanine-DNA Methyltransferase - genetics ; Polymerase Chain Reaction - methods ; Promoter Regions, Genetic ; Proto-Oncogene Proteins - genetics ; Proto-Oncogene Proteins p21(ras) ; ras Proteins ; Risk Factors ; Sensitivity and Specificity ; Sequence Analysis, DNA ; Stomach. Duodenum. Small intestine. Colon. Rectum. Anus ; Sulfites ; Tumor Suppressor Protein p53 - genetics ; Tumors</subject><ispartof>JNCI : Journal of the National Cancer Institute, 2005-09, Vol.97 (18), p.1330-1338</ispartof><rights>2005 INIST-CNRS</rights><rights>Copyright Oxford University Press(England) Sep 21, 2005</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c516t-e20f938faf885d3a715d6bc9a3933a138c27a15ed0e21c15e19e84ce9ebe47bf3</citedby><cites>FETCH-LOGICAL-c516t-e20f938faf885d3a715d6bc9a3933a138c27a15ed0e21c15e19e84ce9ebe47bf3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,776,780,27901,27902</link.rule.ids><backlink>$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=17175735$$DView record in Pascal Francis$$Hfree_for_read</backlink><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/16174854$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Shen, Lanlan</creatorcontrib><creatorcontrib>Kondo, Yutaka</creatorcontrib><creatorcontrib>Rosner, Gary L.</creatorcontrib><creatorcontrib>Xiao, Lianchun</creatorcontrib><creatorcontrib>Hernandez, Natalie Supunpong</creatorcontrib><creatorcontrib>Vilaythong, Jill</creatorcontrib><creatorcontrib>Houlihan, P. Scott</creatorcontrib><creatorcontrib>Krouse, Robert S.</creatorcontrib><creatorcontrib>Prasad, Anil R.</creatorcontrib><creatorcontrib>Einspahr, Janine G.</creatorcontrib><creatorcontrib>Buckmeier, Julie</creatorcontrib><creatorcontrib>Alberts, David S.</creatorcontrib><creatorcontrib>Hamilton, Stanley R.</creatorcontrib><creatorcontrib>Issa, Jean-Pierre J.</creatorcontrib><title>MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer</title><title>JNCI : Journal of the National Cancer Institute</title><addtitle>JNCI J Natl Cancer Inst</addtitle><description>Background: Sporadic colorectal cancers often arise from a region of cells characterized by a “field defect” that has not been well defined molecularly. DNA methylation has been proposed as a candidate mediator of this field defect. The DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) is frequently methylated in colorectal cancer. We hypothesized that MGMT methylation could be one of the mediators of field cancerization in the colon mucosa. Methods: We studied MGMT promoter methylation by three different bisulfite-based techniques in tumor, adjacent mucosa, and nonadjacent mucosa from 95 colorectal cancer patients and in colon mucosa from 33 subjects with no evidence of cancer. Statistical tests were two-sided. Results: MGMT promoter methylation was present in 46% of the tumors. Patients whose cancer had MGMT promoter methylation also had substantial MGMT promoter methylation in apparently normal adjacent mucosa. This methylation was seen with a quantitative assay in 50% (22/44; 95% confidence interval [CI] = 34% to 65%) of normal samples with MGMT promoter methylation in the adjacent tumors, 6% (3/51; 95% CI = 1% to 16%) of samples without MGMT methylation in adjacent tumors, and 12% (4/33; 95% CI = 3% to 28%) of control samples (P<.001 for comparison between each of the latter two groups and the first group). MGMT methylation was detected with a more sensitive assay in 94%, 34%, and 27% of these samples, respectively (P<.001). In grossly normal colonic mucosa of colon cancer patients, methylation was detected 10 cm away from the tumor in 10 of 13 cases. Tumors with MGMT promoter methylation had a higher rate of G-to-A mutation in the KRAS oncogene than tumors without MGMT promoter methylation (10/42 versus 3/46, P = .03). Using a sensitive mutant allele-specific amplification assay for KRAS mutations, we also found KRAS mutations in 12% (3/25; 95% CI = 2.5% to 31%) of colorectal mucosas with detectable MGMT methylation and 3% (2/64; 95% CI = 0.4% to 11%) of colorectal mucosas without MGMT methylation (P = .13). Conclusion: Some colorectal cancers arise from a field defect defined by epigenetic inactivation of MGMT. Detection of this abnormality may ultimately be useful in risk assessment for colorectal cancer.</description><subject>Biological and medical sciences</subject><subject>Biomarkers, Tumor - genetics</subject><subject>Cell Line, Tumor</subject><subject>Clinical trials</subject><subject>Colorectal cancer</subject><subject>Colorectal Neoplasms - enzymology</subject><subject>Colorectal Neoplasms - genetics</subject><subject>Colorectal Neoplasms - pathology</subject><subject>Deoxyribonucleic acid</subject><subject>DNA</subject><subject>DNA Methylation</subject><subject>Epigenesis, Genetic</subject><subject>Gastroenterology. Liver. Pancreas. Abdomen</subject><subject>Gene Silencing</subject><subject>Humans</subject><subject>Intestinal Mucosa - enzymology</subject><subject>Intestinal Mucosa - pathology</subject><subject>Medical sciences</subject><subject>Mutation</subject><subject>O-Methylguanine-DNA Methyltransferase - genetics</subject><subject>Polymerase Chain Reaction - methods</subject><subject>Promoter Regions, Genetic</subject><subject>Proto-Oncogene Proteins - genetics</subject><subject>Proto-Oncogene Proteins p21(ras)</subject><subject>ras Proteins</subject><subject>Risk Factors</subject><subject>Sensitivity and Specificity</subject><subject>Sequence Analysis, DNA</subject><subject>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</subject><subject>Sulfites</subject><subject>Tumor Suppressor Protein p53 - genetics</subject><subject>Tumors</subject><issn>0027-8874</issn><issn>1460-2105</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2005</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqF0c1rFDEYBvBQlHZbPXkvQdCLjM33x1G2tmvpotBqxUvIZt6hWWcn22QW2v_eLLtY8GIuCcmPB_I-CL2h5CMllp8thxDP2mVkWh6gCRWKNIwS-QJNCGG6MUaLI3RcypLUZZk4REdUUS2MFBM0m1_Ob_G3nFZphIznMN4_9X6MacB-aPFFhL7F59BBGHEc8M06Zd_GgKepT7le-h5P_RAgv0IvO98XeL3fT9D3i8-301lz_fXyy_TTdRMkVWMDjHSWm853xsiWe01lqxbBem4595SbwLSnEloCjIZ6oBaMCGBhAUIvOn6C3u9y1zk9bKCMbhVLgL73A6RNccooooQm_4WMCG4p0xW-_Qcu0yYP9ROOMWKNIVRU9GGHQk6lZOjcOseVz0-OEretwW1rcLsaqj7dR24WK2if7X7uFbzbA1-C77tcZxjLs9NUS823Qc3OxTLC4993n387pbmWbvbzl_txd3dDr66IU_wPbameww</recordid><startdate>20050921</startdate><enddate>20050921</enddate><creator>Shen, Lanlan</creator><creator>Kondo, Yutaka</creator><creator>Rosner, Gary L.</creator><creator>Xiao, Lianchun</creator><creator>Hernandez, Natalie Supunpong</creator><creator>Vilaythong, Jill</creator><creator>Houlihan, P. Scott</creator><creator>Krouse, Robert S.</creator><creator>Prasad, Anil R.</creator><creator>Einspahr, Janine G.</creator><creator>Buckmeier, Julie</creator><creator>Alberts, David S.</creator><creator>Hamilton, Stanley R.</creator><creator>Issa, Jean-Pierre J.</creator><general>Oxford University Press</general><general>Oxford Publishing Limited (England)</general><scope>BSCLL</scope><scope>IQODW</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7TO</scope><scope>7U7</scope><scope>7U9</scope><scope>C1K</scope><scope>H94</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7U1</scope><scope>7U2</scope><scope>7X8</scope></search><sort><creationdate>20050921</creationdate><title>MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer</title><author>Shen, Lanlan ; Kondo, Yutaka ; Rosner, Gary L. ; Xiao, Lianchun ; Hernandez, Natalie Supunpong ; Vilaythong, Jill ; Houlihan, P. Scott ; Krouse, Robert S. ; Prasad, Anil R. ; Einspahr, Janine G. ; Buckmeier, Julie ; Alberts, David S. ; Hamilton, Stanley R. ; Issa, Jean-Pierre J.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c516t-e20f938faf885d3a715d6bc9a3933a138c27a15ed0e21c15e19e84ce9ebe47bf3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2005</creationdate><topic>Biological and medical sciences</topic><topic>Biomarkers, Tumor - genetics</topic><topic>Cell Line, Tumor</topic><topic>Clinical trials</topic><topic>Colorectal cancer</topic><topic>Colorectal Neoplasms - enzymology</topic><topic>Colorectal Neoplasms - genetics</topic><topic>Colorectal Neoplasms - pathology</topic><topic>Deoxyribonucleic acid</topic><topic>DNA</topic><topic>DNA Methylation</topic><topic>Epigenesis, Genetic</topic><topic>Gastroenterology. Liver. Pancreas. Abdomen</topic><topic>Gene Silencing</topic><topic>Humans</topic><topic>Intestinal Mucosa - enzymology</topic><topic>Intestinal Mucosa - pathology</topic><topic>Medical sciences</topic><topic>Mutation</topic><topic>O-Methylguanine-DNA Methyltransferase - genetics</topic><topic>Polymerase Chain Reaction - methods</topic><topic>Promoter Regions, Genetic</topic><topic>Proto-Oncogene Proteins - genetics</topic><topic>Proto-Oncogene Proteins p21(ras)</topic><topic>ras Proteins</topic><topic>Risk Factors</topic><topic>Sensitivity and Specificity</topic><topic>Sequence Analysis, DNA</topic><topic>Stomach. Duodenum. Small intestine. Colon. Rectum. Anus</topic><topic>Sulfites</topic><topic>Tumor Suppressor Protein p53 - genetics</topic><topic>Tumors</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Shen, Lanlan</creatorcontrib><creatorcontrib>Kondo, Yutaka</creatorcontrib><creatorcontrib>Rosner, Gary L.</creatorcontrib><creatorcontrib>Xiao, Lianchun</creatorcontrib><creatorcontrib>Hernandez, Natalie Supunpong</creatorcontrib><creatorcontrib>Vilaythong, Jill</creatorcontrib><creatorcontrib>Houlihan, P. Scott</creatorcontrib><creatorcontrib>Krouse, Robert S.</creatorcontrib><creatorcontrib>Prasad, Anil R.</creatorcontrib><creatorcontrib>Einspahr, Janine G.</creatorcontrib><creatorcontrib>Buckmeier, Julie</creatorcontrib><creatorcontrib>Alberts, David S.</creatorcontrib><creatorcontrib>Hamilton, Stanley R.</creatorcontrib><creatorcontrib>Issa, Jean-Pierre J.</creatorcontrib><collection>Istex</collection><collection>Pascal-Francis</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>Oncogenes and Growth Factors Abstracts</collection><collection>Toxicology Abstracts</collection><collection>Virology and AIDS Abstracts</collection><collection>Environmental Sciences and Pollution Management</collection><collection>AIDS and Cancer Research Abstracts</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>Risk Abstracts</collection><collection>Safety Science and Risk</collection><collection>MEDLINE - Academic</collection><jtitle>JNCI : Journal of the National Cancer Institute</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Shen, Lanlan</au><au>Kondo, Yutaka</au><au>Rosner, Gary L.</au><au>Xiao, Lianchun</au><au>Hernandez, Natalie Supunpong</au><au>Vilaythong, Jill</au><au>Houlihan, P. Scott</au><au>Krouse, Robert S.</au><au>Prasad, Anil R.</au><au>Einspahr, Janine G.</au><au>Buckmeier, Julie</au><au>Alberts, David S.</au><au>Hamilton, Stanley R.</au><au>Issa, Jean-Pierre J.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer</atitle><jtitle>JNCI : Journal of the National Cancer Institute</jtitle><addtitle>JNCI J Natl Cancer Inst</addtitle><date>2005-09-21</date><risdate>2005</risdate><volume>97</volume><issue>18</issue><spage>1330</spage><epage>1338</epage><pages>1330-1338</pages><issn>0027-8874</issn><eissn>1460-2105</eissn><coden>JNCIEQ</coden><abstract>Background: Sporadic colorectal cancers often arise from a region of cells characterized by a “field defect” that has not been well defined molecularly. DNA methylation has been proposed as a candidate mediator of this field defect. The DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT) is frequently methylated in colorectal cancer. We hypothesized that MGMT methylation could be one of the mediators of field cancerization in the colon mucosa. Methods: We studied MGMT promoter methylation by three different bisulfite-based techniques in tumor, adjacent mucosa, and nonadjacent mucosa from 95 colorectal cancer patients and in colon mucosa from 33 subjects with no evidence of cancer. Statistical tests were two-sided. Results: MGMT promoter methylation was present in 46% of the tumors. Patients whose cancer had MGMT promoter methylation also had substantial MGMT promoter methylation in apparently normal adjacent mucosa. This methylation was seen with a quantitative assay in 50% (22/44; 95% confidence interval [CI] = 34% to 65%) of normal samples with MGMT promoter methylation in the adjacent tumors, 6% (3/51; 95% CI = 1% to 16%) of samples without MGMT methylation in adjacent tumors, and 12% (4/33; 95% CI = 3% to 28%) of control samples (P<.001 for comparison between each of the latter two groups and the first group). MGMT methylation was detected with a more sensitive assay in 94%, 34%, and 27% of these samples, respectively (P<.001). In grossly normal colonic mucosa of colon cancer patients, methylation was detected 10 cm away from the tumor in 10 of 13 cases. Tumors with MGMT promoter methylation had a higher rate of G-to-A mutation in the KRAS oncogene than tumors without MGMT promoter methylation (10/42 versus 3/46, P = .03). Using a sensitive mutant allele-specific amplification assay for KRAS mutations, we also found KRAS mutations in 12% (3/25; 95% CI = 2.5% to 31%) of colorectal mucosas with detectable MGMT methylation and 3% (2/64; 95% CI = 0.4% to 11%) of colorectal mucosas without MGMT methylation (P = .13). Conclusion: Some colorectal cancers arise from a field defect defined by epigenetic inactivation of MGMT. Detection of this abnormality may ultimately be useful in risk assessment for colorectal cancer.</abstract><cop>Cary, NC</cop><pub>Oxford University Press</pub><pmid>16174854</pmid><doi>10.1093/jnci/dji275</doi><tpages>9</tpages><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 0027-8874 |
| ispartof | JNCI : Journal of the National Cancer Institute, 2005-09, Vol.97 (18), p.1330-1338 |
| issn | 0027-8874 1460-2105 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_68606470 |
| source | Oxford University Press Journals All Titles (1996-Current); MEDLINE; Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals |
| subjects | Biological and medical sciences Biomarkers, Tumor - genetics Cell Line, Tumor Clinical trials Colorectal cancer Colorectal Neoplasms - enzymology Colorectal Neoplasms - genetics Colorectal Neoplasms - pathology Deoxyribonucleic acid DNA DNA Methylation Epigenesis, Genetic Gastroenterology. Liver. Pancreas. Abdomen Gene Silencing Humans Intestinal Mucosa - enzymology Intestinal Mucosa - pathology Medical sciences Mutation O-Methylguanine-DNA Methyltransferase - genetics Polymerase Chain Reaction - methods Promoter Regions, Genetic Proto-Oncogene Proteins - genetics Proto-Oncogene Proteins p21(ras) ras Proteins Risk Factors Sensitivity and Specificity Sequence Analysis, DNA Stomach. Duodenum. Small intestine. Colon. Rectum. Anus Sulfites Tumor Suppressor Protein p53 - genetics Tumors |
| title | MGMT Promoter Methylation and Field Defect in Sporadic Colorectal Cancer |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-05T01%3A11%3A14IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=MGMT%20Promoter%20Methylation%20and%20Field%20Defect%20in%20Sporadic%20Colorectal%20Cancer&rft.jtitle=JNCI%20:%20Journal%20of%20the%20National%20Cancer%20Institute&rft.au=Shen,%20Lanlan&rft.date=2005-09-21&rft.volume=97&rft.issue=18&rft.spage=1330&rft.epage=1338&rft.pages=1330-1338&rft.issn=0027-8874&rft.eissn=1460-2105&rft.coden=JNCIEQ&rft_id=info:doi/10.1093/jnci/dji275&rft_dat=%3Cproquest_cross%3E20439127%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=220988014&rft_id=info:pmid/16174854&rfr_iscdi=true |